The urge to merge in the pharmaceutical industry
Author
Abstract
Suggested Citation
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Ye Jin Lee & Kwangsoo Shin & Eungdo Kim, 2019. "The Influence of a Firm’s Capability and Dyadic Relationship of the Knowledge Base on Ambidextrous Innovation in Biopharmaceutical M&As," Sustainability, MDPI, vol. 11(18), pages 1-17, September.
- Wei Teng, Chih & Foley, Lucy & O'Neill, Peter & Hicks, Chris, 2014. "An analysis of supply chain strategies in the regenerative medicine industry—Implications for future development," International Journal of Production Economics, Elsevier, vol. 149(C), pages 211-225.
- Katsaliaki, Korina & Kumar, Sameer & Loulos, Vasilis, 2024. "Supply chain coopetition: A review of structures, mechanisms and dynamics," International Journal of Production Economics, Elsevier, vol. 267(C).
- Wajid, Abdul & Khan, Kashif Hasan & Handa, Harish, 2022. "Innovations Through Mergers and Acquisitions in the Pharmaceutical Sector," EconStor Open Access Book Chapters, in: Technological Innovations for Sustainability and Business Growth, pages 91-104, ZBW - Leibniz Information Centre for Economics.
- Jeffrey Pfeffer & Christina T. Fong, 2005. "Building Organization Theory from First Principles: The Self-Enhancement Motive and Understanding Power and Influence," Organization Science, INFORMS, vol. 16(4), pages 372-388, August.
- Pedro Domingos Antoniolli, 2016. "Information Technology Framework for Pharmaceutical Supply Chain Demand Management: a Brazilian Case Study," Brazilian Business Review, Fucape Business School, vol. 13(2), pages 27-55, March.
- Park, Sungwook & Kwon, Youngsun, 2023. "Disentangling the effects on OTT platform performance of three strategies: Pricing, M&As, and content investments," Telecommunications Policy, Elsevier, vol. 47(8).
More about this item
Keywords
Glaxo SmithKline Mergers Pharmaceutical industry Shareholder value;Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:eurman:v:19:y:2001:i:4:p:430-437. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/wps/find/journaldescription.cws_home/115/description#description .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.